rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ACRS
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Aclaris Therapeutics (ACRS) Gets a Buy from Leerink Partners

      Tipranks Press Release.

      11h agoThe Globe and MailACRS
      This Aclaris Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
      Nov 17BenzingaACRSSWK
      H.C. Wainwright reiterates Aclaris stock rating after trial miss
      Nov 17Investing.comACRS
      Wedbush cuts Aclaris Therapeutics stock rating on trial miss
      Nov 17Investing.comACRS
      Why is Aclaris Therapeutics stock sliding today?
      Nov 16Investing.comACRS
      Aclaris stock falls after atopic dermatitis trial fails
      Nov 16Investing.comACRS
      Aclaris Therapeutics’ mAb fails in Phase II eczema trial
      Nov 16Yahoo FinanceACRS
      Why is Aclaris Therapeutics Stock Trading Lower on Monday?
      Nov 16BenzingaACRS
      Aclaris Therapeutics, Summit Therapeutics And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
      Nov 16BenzingaACRSSMMT
      Aclaris Therapeutics at Jefferies Global Healthcare Conference: pipeline reset
      Nov 16Investing.comACRS
      Aclaris phase 2 atopic dermatitis trial fails primary endpoint
      Nov 16Investing.comACRS
      Aclaris Therapeutics Initiates Phase 2b Trial of Modzatinib (ATI-2138) in Lichen Planus (LP)
      Nov 16Yahoo FinanceACRS
      Aclaris Therapeutics Announces Top Line Phase 2 Results for its Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) in Atopic Dermatitis (AD)
      Nov 16Yahoo FinanceACRS
      Aclaris Therapeutics to Participate in the Jefferies Global Healthcare Conference
      Nov 12Yahoo FinanceACRSJEF
      Aclaris Therapeutics Inc earnings beat by $0.04, revenue topped estimates
      Nov 5Investing.comACRS
      Aclaris Therapeutics (ACRS) Reports Q3 Loss, Beats Revenue Estimates

      Aclaris (ACRS) delivered earnings and revenue surprises of +25.00% and +16.16%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

      Nov 5Yahoo FinanceACRS
      Aclaris: Q3 Earnings Snapshot
      Nov 5Yahoo FinanceACRS
      Aclaris Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate and Clinical Update
      Nov 5Yahoo FinanceACRS
      Aclaris Therapeutics, Inc. (ACRS) Discusses ATI-052 Proof-of-Concept Results in Atopic Dermatitis and Asthma - Slideshow (NASDAQ:ACRS) 2026-10-29
      Oct 29Seeking AlphaACRS
      Wedbush Cuts Price Target on Aclaris Therapeutics to $8 From $10, Keeps Outperform Rating
      Oct 28Yahoo FinanceACRS
      Aclaris Therapeutics ATI-052 Posts Early Eczema, Asthma Signals in Phase 1b
      Oct 27Yahoo FinanceACRS
      Aclaris Says Early Data Validates Dual-Target Approach for Eczema, Asthma Drug
      Oct 27BenzingaACRS
      Aclaris Reports Positive Asthma, Eczema Drug Trial Results — So, Why Is ACRS Stock Down Nearly 8%?
      Oct 27Yahoo FinanceACRS
      Aclaris prices $50M stock offering at $3.50 per share
      Oct 27Investing.comACRS
      Aclaris reports positive phase 1b trial results for ATI-052
      Oct 27Investing.comACRS
      Aclaris Therapeutics Announces Positive Phase 1b Proof-of-Concept Primary Analysis Results for its Anti-TSLP/IL-4Rα Bispecific ATI-052 in Atopic Dermatitis (AD) and Asthma
      Oct 27Yahoo FinanceACRS
      Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
      Oct 21Yahoo FinanceACRS
      Analysts Have Conflicting Sentiments on These Healthcare Companies: Aclaris Therapeutics (ACRS), Globus Medical (GMED) and Johnson & Johnson (JNJ)

      Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

      Oct 8The Globe and MailACRSOKYOGMEDJNJ
      Cantor Fitzgerald reiterates Aclaris Therapeutics stock rating
      Oct 2Investing.comACRS
      Cantor Fitzgerald reiterates Aclaris stock rating on LP opportunity
      Sep 24Investing.comACRS
      Cantor Fitzgerald reiterates Aclaris Therapeutics stock rating
      Sep 16Investing.comACRS
      Aclaris (ACRS) Soars 6.0%: Is Further Upside Left in the Stock?

      Aclaris (ACRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

      Sep 15Yahoo FinanceACRS
      Aclaris at Cantor Fitzgerald conference: pipeline, cash, catalysts
      Sep 10Investing.comACRS
      Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

      WAYNE, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Thursday, September 10, 2026, at 2:45 PM ET, Aclaris’ Chief Executive Officer Dr. Neal Walker will participate in a fireside chat during the 2026 Cantor Global Healthcare Conference in New York, NY. A live and archived webcast of this event will be accessible on

      Sep 3Yahoo FinanceACRS
      Canaccord initiates Aclaris stock with buy rating on pipeline potential
      Sep 1Investing.comACRS
      Canaccord Genuity Initiates Aclaris Therapeutics at Buy With $10 Price Target

      Aclaris Therapeutics (ACRS) has an average rating of buy and mean price target of $10.58, according

      Sep 1Yahoo FinanceACRS
      Piper Sandler reiterates Aclaris stock rating on asthma data
      Aug 31Investing.comACRS

      This is the newest page. Registered accounts read further back.